Omeros Corporation (NASDAQ:OMER) Receives $40.33 Consensus PT from Analysts

Omeros Corporation (NASDAQ:OMER) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $40.3333.

Several research analysts have recently commented on the company. WBB Securities reiterated a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a research note on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. HC Wainwright upped their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Wednesday, October 15th.

Insider Activity

In other news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 12.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its holdings in shares of Omeros by 16.5% during the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 1,004 shares in the last quarter. Russell Investments Group Ltd. increased its position in Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 5,677 shares during the period. B. Riley Wealth Advisors Inc. acquired a new stake in Omeros in the 2nd quarter worth about $32,000. Tower Research Capital LLC TRC boosted its holdings in Omeros by 829.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,971 shares during the period. Finally, Sei Investments Co. bought a new stake in Omeros in the 2nd quarter valued at about $40,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Price Performance

Shares of OMER stock opened at $11.72 on Tuesday. The company has a fifty day moving average price of $12.05 and a two-hundred day moving average price of $7.68. Omeros has a one year low of $2.95 and a one year high of $17.65. The stock has a market cap of $830.95 million, a P/E ratio of -5.80 and a beta of 2.38.

Omeros (NASDAQ:OMER) last issued its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.39. As a group, equities research analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.